Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. L-Lysine increased the cytotoxicity effect of doxorubicin in MDA-MB-231 and MDA-MB-468 breast cancer cell lines

    Research output: Contribution to journalConference abstract in journalResearch

  2. TSGA10 and H2AX competition over binding HIF-1 in breast cancer

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  1. Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Tertiary lymphoid structures improve immunotherapy and survival in melanoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The real-world outcome of metastatic melanoma: Unknown primary vs. known cutaneous

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Long-Term Exposure to Inflammation Induces Differential Cytokine Patterns and Apoptosis in Dendritic Cells

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Y J L Jansen
  • E A Rozeman
  • R Mason
  • S M Goldinger
  • M H Geukes Foppen
  • L Hoejbergs
  • H Schmidt
  • J V van Thienen
  • J B A G Haanen
  • L Tiainen
  • I Marie Svane
  • S Mäkelä
  • T Seremet
  • A Arance
  • R Dummer
  • L Bastholt
  • M Nyakas
  • O Straume
  • A M Menzies
  • G V Long
  • V Atkinson
  • C U Blank
  • B Neyns
View graph of relations

BACKGROUND: PD-1 blocking monoclonal antibodies improve the overall survival of patients with advanced melanoma but the optimal duration of treatment has not been established.

PATIENTS AND METHODS: This academic real-world cohort study investigated the outcome of 185 advanced melanoma patients who electively discontinued anti-PD-1 therapy with pembrolizumab (N = 167) or nivolumab (N = 18) in the absence of disease progression (PD) or treatment-limiting toxicity (TLT) at 14 medical centres across Europe and Australia.

RESULTS: Median time on treatment was 12 months (range 0.7-43). The best objective tumour response at the time of treatment discontinuation was complete response (CR) in 117 (63%) patients, partial response (PR) in 44 (24%) patients, and stable disease (SD) in 16 (9%) patients; 8 (4%) patients had no evaluable disease (NE). After a median follow-up of 18 months (range 0.7-48) after treatment discontinuation, 78% of patients remained free of progression. Median time to progression was 12 months (range 2-23). PD was less frequent in patients with CR (14%) compared to patients with PR (32%) and SD (50%). Six out of 19 (32%) patients who were retreated with an anti-PD-1 at the time of PD obtained a new anti-tumour response.

CONCLUSIONS: In this real-world cohort of advanced melanoma patients discontinuing anti-PD-1 therapy in the absence of TLT or PD, the duration of anti-PD-1 therapy was shorter when compared to clinical trials. In patients obtaining a CR, and being treated for more than 6 months, the risk of relapse after treatment discontinuation was low. Patients achieving a PR or SD as best tumour response were at higher risk for progression after discontinuing therapy, and defining optimal treatment duration in such patients deserves further study. Retreatment with an anti-PD-1 at the time of progression may lead to renewed anti-tumour activity in some patients.Clinical trial registration: NCT02673970 (https://clinicaltrials.gov/ct2/show/NCT02673970?cond=melanoma&cntry=BE&city=Jette&rank=3).

Original languageEnglish
JournalAnnals of Oncology
ISSN0923-7534
DOIs
Publication statusPublished - Jul 2019

ID: 57729794